Strong market potential
Clear drivers in a growing and non-cyclical market
The pediatric medical device segment remains underdeveloped and is experiencing strong growth. With its patented technology and recurring revenue potential from single-use disposables, Neola® aims to set a new standard of care in neonatal intensive care worldwide, commercialized following regulatory approvals.
- Global market
- High margins
- Growing patient population
The Medtech Landscape
The global MedTech industry today generates revenues exceeding USD 500 billion, source. Neola Medical estimates that the vast majority of medical devices have been developed primarily for adults, while pediatric devices lag behind by five to ten years. Several factors contribute to this gap, including children’s ongoing physiological development, challenges in conducting clinical studies, as well as profitability and reimbursement structures.
Market Opportunity
2With our medical device, we are entering a growing and non-cyclical market supported by favorable trends and clear drivers. The global market for neonatal respiratory care devices was valued at USD 1.6 billion in 2025 to USD 2.2 billion by 2032, exhibiting a CAGR of 4.9%, source. This growth is further reinforced by increasing regulatory focus on pediatric medical devices, aligned with the United Nations’ Agenda 2030 target (Goal 3.2) to reduce preventable infant mortality, source.
Neonatal Market Drivers
Focus market
The U.S. is a particularly attractive market, with more than 35,600 neonatal care beds and a high rate of preterm births, source. According to our market analysis, conducted with U.S. neonatologists and hospital directors, approximately 50–70% of these beds are considered relevant for our medical device, Neola®, with an average ward comprising 40–50 beds (MCRA Market Analysis US 2022).
Strategy
Neola Medial’s strategy is to establish Neola® immediately after FDA market authorization at one to three hospitals with large neonatal intensive care units. The goal is to demonstrate a profitable market entry, a well-functioning distribution model, and clear benefits for both hospitals and patients.
Target group
Teaching hospitals are a key initial target for Neola Medical, as they invest early in new technologies and play a central role in research, training, and receiving significant public and private funding. Neola Medical has identified ten teaching hospitals with NICUs as the company’s primary target group in its first commercial phase, source.
Reimbursement
Understanding the U.S. reimbursement systems is essential for Neola Medical’s commercialization plan. In collaboration with a leading U.S. consulting firm, the company has developed a reimbursement and pricing strategy tailored to the American healthcare and insurance market.
Total Addressable Market (TAM) for Neola® and its disposables. The figures are based on the company’s own calculations as well as a scientific publication, source.
NICU: Neonatal Intensive Care Unit, where preterm and critically ill newborns receive advanced medical care.
Explore more of Neola Medical as an Investment
4. Scalable Business Model
Neola Medical applies a razor-and-blades model: sales of the Neola® device combined with recurring revenue from disposable probe sets. This structure offers scalability, attractive margins, and predictable revenue streams once the product is launched.